Checkpoint inhibitors in advanced nonsmall-cell lung cancer; a Bayesian network meta-analysis
J Cancer Res Ther
;
2020 Sep; 16(4): 828-838
Article
| IMSEAR
| ID: sea-213711
ABSTRACT
Background:
Checkpoint inhibitors (CPIs) have improved survival compared to chemotherapy alone in advanced nonsmall-cell lung cancer (NSCLC). This article aims to compare indirect evidence and rank the effect of different CPIs in this setting. Materials andMethods:
In this network meta-analysis, we searched for trials comparing CPIs in advanced NSCLC. Figures for survival endpoints were extracted. In addition, a network meta-regression analysis was carried out.Results:
A total of 9220 patients from 16 trials were included in the analysis. In the first-line setting, for the overall survival endpoint, the chemotherapy + Pembrolizumab combination had the highest effectivity rank probability as compared to chemotherapy (hazard ratio = 0.788, 95% credential interval = 0.728–0.855). For the second-line setting, and also for the efficacy in terms of progression-free survival, various CPIs and their combinations were ranked.Conclusion:
Some degree of differences in terms of efficacy exists between different types, dosages, settings, and combinations of CPI. We quantify these differences to guide clinical practice
Full text:
Available
Index:
IMSEAR (South-East Asia)
Type of study:
Systematic reviews
Journal:
J Cancer Res Ther
Journal subject:
Neoplasms
/
Therapeutics
Year:
2020
Type:
Article
Similar
MEDLINE
...
LILACS
LIS